STOPPING SALES LEAKAGE Where and why are sales slipping through the cracks? 15,823,423.10 Units lost to sales leakage in a 26 week period. Immunosuppressant 952,090.50 Leakage by **Treatment HIV Treatments** 1,859,652.60 Diabetic Treatments Hemophilia A 2,151,801.90 8,104,261.47

#1 Loss Source:

Hemophilia

the highest market share,

Recombinate Eloctate® Kogenate® FS | Stimate® Advate Other

A disorder in which blood doesn't clot normally.

16.6% Spending Increase in 2015*

AmerisourceBergen sells only 2.

% of Market Share

#2 Loss Source:

Of the top 5 hemophilia drugs with

Top Sellers 1. Metformin Lantus Glipizide

Diabetic Treatments

14% spending increase in 2015*

4. Glimepiride

- 5. Humalog

1. Truvada 🗸 2. Atripla

Top Sellers

#3 Loss Source:

HIV Treatments

16.6% spending increase in 2015*

3. Norvir 4. Stribild

5. Viread

How do we fix it?

market research.

Identify competitors

Poll buying groups

Understand patient needs

Reevaluate marketing strategies.

Conduct

Raise awareness Contribute to research

Satisfy

effectiveness

Promote drug

For specialty illnesses:

 Sell all top drugs for each specialty illness

all pharmacy needs.

Price competitively

AmerisourceBergen Challenge

Sofia Spadotto | TUG85148 FOX SCHOOL OF BUSINESS

Madison Collins | TUH15673

FOX SCHOOL OF BUSINESS

Joshua Kim | TUG84802 FOX SCHOOL OF BUSINESS